Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BFRI 
Biofrontera Inc (BFRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BFRI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.1% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.74M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 0.54 | 52 Weeks Range 0.54 - 1.25 | Updated Date 11/2/2025 |
52 Weeks Range 0.54 - 1.25 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.34% | Operating Margin (TTM) -56.25% |
Management Effectiveness
Return on Assets (TTM) -48.85% | Return on Equity (TTM) -531.54% |
Valuation
Trailing PE - | Forward PE 13 | Enterprise Value 8851179 | Price to Sales(TTM) 0.3 |
Enterprise Value 8851179 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 10668442 | Shares Floating 8257054 |
Shares Outstanding 10668442 | Shares Floating 8257054 | ||
Percent Insiders 14.85 | Percent Institutions 21.29 |
Upturn AI SWOT
Biofrontera Inc
Company Overview
History and Background
Biofrontera Inc., founded in 1997, is a biopharmaceutical company specializing in the development and commercialization of dermatological drugs and medical devices. Initially focused on Europe, the company expanded into the US market, becoming a publicly traded entity in 2015. Significant milestones include the FDA approval and subsequent commercialization of Ameluzu00ae and Xepiu2122.
Core Business Areas
- Photodynamic Therapy (PDT): Develops and markets Ameluzu00ae in combination with the RhodoLEDu00ae lamp for the treatment of actinic keratoses, a pre-cancerous skin condition.
- Topical Antibiotic: Markets Xepiu2122, a topical oxaborole antifungal for the treatment of impetigo.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives overseeing various departments such as sales, marketing, R&D, and regulatory affairs. Biofrontera Inc. operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Ameluzu00ae: Ameluzu00ae is a topical prescription drug used in photodynamic therapy (PDT) with the RhodoLEDu00ae lamp to treat actinic keratoses. Market share data is dynamic, but Biofrontera holds a significant position in the PDT market for AK treatment. Competitors include other PDT treatments and topical creams like 5-fluorouracil and imiquimod. Exact revenue figures are difficult to ascertain without proprietary access to the company's financial records.
- Xepiu2122: Xepiu2122 is a topical oxaborole antifungal for the treatment of impetigo. Competitors include mupirocin and retapamulin. Market share for Xepi is less dominant than Ameluz. Exact revenue figures are difficult to ascertain without proprietary access to the company's financial records.
Market Dynamics
Industry Overview
The dermatological market is driven by aging populations, increased awareness of skin health, and advancements in treatment options. It's a growing market with increasing demand for both therapeutic and aesthetic solutions.
Positioning
Biofrontera Inc. is positioned as a specialty pharmaceutical company focused on innovative dermatological treatments, particularly in photodynamic therapy. Its competitive advantage lies in the efficacy and safety profile of Ameluzu00ae and its delivery system (RhodoLEDu00ae).
Total Addressable Market (TAM)
The total addressable market for actinic keratosis treatment is estimated in the billions of dollars globally. Biofrontera Inc. is positioned to capture a share of this market through continued commercialization and expansion.
Upturn SWOT Analysis
Strengths
- Proprietary PDT technology (Ameluzu00ae and RhodoLEDu00ae)
- Established sales and marketing infrastructure in key markets
- Growing awareness of PDT for actinic keratosis treatment
- FDA approved products
Weaknesses
- Dependence on Ameluzu00ae for revenue
- Relatively small market capitalization
- Competition from established pharmaceutical companies
- Pricing pressures
Opportunities
- Expansion into new geographic markets
- Development of new dermatological products
- Partnerships and collaborations with other companies
- Increasing awareness and adoption of PDT
- Potential for new indications for Ameluzu00ae
Threats
- Competition from generic drugs and biosimilars
- Changes in reimbursement policies
- Regulatory hurdles
- Economic downturn
- Development of alternative therapies
Competitors and Market Share
Key Competitors
- LEO Pharma (LEO)
- Galderma (Nestle)
- Sun Pharmaceutical (SUNPHARMA.NS)
Competitive Landscape
Biofrontera Inc. faces competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its proprietary PDT technology and focused expertise in dermatology.
Growth Trajectory and Initiatives
Historical Growth: Biofrontera Inc.'s growth has been driven by the commercial success of Ameluzu00ae and Xepiu2122.
Future Projections: Future growth is projected to be driven by continued expansion into new markets, label extensions, and new product development. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new marketing campaigns, and pursuing regulatory approvals in new territories.
Summary
Biofrontera Inc. is a smaller biopharmaceutical company with a focus on dermatological treatments, particularly actinic keratosis. While it possesses a strong proprietary technology in Ameluzu00ae, it faces challenges related to competition and financial stability. The company needs to expand product line and increase its market share to become stronger and look out for competitive threats from larger companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Third-party financial data providers (e.g., Yahoo Finance, Google Finance)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may not be completely accurate or up-to-date. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.